Mesoblast (NASDAQ:MESO) Director Gregory George Purchases 1,586,890 Shares

Key Points

• Gregory George bought 1,586,890 Mesoblast shares on April 9 at an average price of $1.44, raising his direct ownership to 13,586,890 shares (about $19.57 million), a 13.22% increase in his position.
• He also executed several other recent purchases — 2,324,072 shares on April 10 at $1.48, 1,981,890 shares on April 9 at $8.59, and 4,000,000 shares on April 4 at $1.42 — totaling roughly 9.89 million shares across those trades.
• The purchases were disclosed in an SEC filing; Mesoblast currently trades near $15 with a 52-week range of $9.75–$21.50 and a consensus analyst rating of Hold.

Mesoblast Limited (NASDAQ:MESO - Get Free Report) Director Gregory George bought 1,586,890 shares of Mesoblast stock in a transaction dated Thursday, April 9th. The stock was acquired at an average cost of $1.44 per share, with a total value of $2,285,121.60. Following the completion of the acquisition, the director directly owned 13,586,890 shares of the company's stock, valued at approximately $19,565,121.60. The trade was a 13.22% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Gregory George also recently made the following trade(s):

• On Friday, April 10th, Gregory George bought 2,324,072 shares of Mesoblast stock. The stock was purchased at an average cost of $1.48 per share, with a total value of $3,439,626.56.
• On Thursday, April 9th, Gregory George purchased 1,981,890 shares of Mesoblast stock. The shares were purchased at an average price of $8.59 per share, with a total value of $17,024,435.10.
• On Saturday, April 4th, Gregory George purchased 4,000,000 shares of Mesoblast stock. The shares were bought at an average cost of $1.42 per share, for a total transaction of $5,680,000.00.

Mesoblast Stock Performance

MESO opened at $15.00 on Monday. The firm's 50 day moving average is $15.65 and its 200-day moving average is $16.81. Mesoblast Limited has a 52-week low of $9.75 and a 52-week high of $21.50. The company has a quick ratio of 1.41, a current ratio of 1.58 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $1.94 billion, a P/E ratio of -27.78 and a beta of 2.19.

Mesoblast (NASDAQ:MESO - Get Free Report) last announced its earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $25.67 million for the quarter. Analysts expect that Mesoblast Limited will post -0.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Mesoblast in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold".

Institutional Investors Weigh In On Mesoblast

A number of institutional investors and hedge funds have recently bought and sold shares of MESO. Caitong International Asset Management Co. Ltd purchased a new position in Mesoblast during the 4th quarter valued at about $32,000. Quadrature Capital Ltd acquired a new stake in shares of Mesoblast during the 4th quarter valued at $479,000. AQR Capital Management LLC grew its holdings in shares of Mesoblast by 80.5% during the 4th quarter. AQR Capital Management LLC now owns 25,215 shares of the company's stock valued at $455,000 after acquiring an additional 11,242 shares in the last quarter. &PARTNERS bought a new stake in Mesoblast during the 4th quarter valued at approximately $334,000. Finally, Opal Capital LLC bought a new stake in Mesoblast during the 4th quarter valued at approximately $307,000. 1.43% of the stock is owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company's most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.